Multiplicity considerations for subgroup analysis subject to consistency constraint.

Area of Science:

• Biostatistics
• Clinical Trial Design
• Pharmacoeconomics

Background:

• Heterogeneity in clinical trial subgroup responses complicates interpretation and can lead to restricted treatment labeling.
• Regulatory bodies acknowledge challenges posed by subgroup response variability.
• Growing interest exists in designing trials to demonstrate efficacy for both the overall population and targeted subgroups.

Purpose of the Study:

• To advocate for setting a treatment effect threshold for subgroups during the trial design phase.
• To guide population labeling decisions when significant overall population findings are established.
• To propose a threshold requirement for the least benefited subgroup to support broad treatment licensing.

Main Methods:

• Advocating for a design-stage threshold on subgroup treatment effects.
• Expanding existing multiplicity approaches to incorporate threshold requirements.
• Investigating the impact of threshold requirements on study power.

Main Results:

• Proposes that broad treatment licensing requires significant overall findings plus the least benefited subgroup meeting a minimum treatment effect threshold.
• If the threshold is not met, treatment would be restricted to the targeted subgroup.
• Thresholds can incorporate clinical considerations like toxicity and adverse events alongside treatment effect.

Conclusions:

• Implementing subgroup treatment effect thresholds at the design stage offers a structured approach to population labeling.
• This method balances demonstrating overall efficacy with ensuring benefit in less responsive subgroups.
• The threshold requirement influences study power and requires careful consideration during trial planning.